Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

BACKGROUND: Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody,...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Joseph M, Oh, Chad K, LaForce, Craig, Miller, S David, Pearlman, David S, Le, Chenxiong, Robbie, Gabriel J, White, Wendy I, White, Barbara, Molfino, Nestor A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058114/
https://www.ncbi.nlm.nih.gov/pubmed/21356110
http://dx.doi.org/10.1186/1471-2466-11-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058114/
https://www.ncbi.nlm.nih.gov/pubmed/21356110
http://dx.doi.org/10.1186/1471-2466-11-14

Ejemplares similares